Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer
Author(s) -
Klaus Holzmann,
Thomas W. Grunt,
Christine Heinzle,
Sandra Sampl,
Heinrich Steinhoff,
Nicole Reichmann,
Miriam Kleiter,
Marlene Hauck,
Brigitte Marian
Publication year - 2011
Publication title -
journal of nucleic acids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.621
H-Index - 32
eISSN - 2090-021X
pISSN - 2090-0201
DOI - 10.1155/2012/950508
Subject(s) - rna splicing , fibroblast growth factor receptor , alternative splicing , carcinogenesis , cancer research , biology , cancer , receptor , splice , computational biology , bioinformatics , fibroblast growth factor , splicing factor , microbiology and biotechnology , rna , genetics , messenger rna , gene
Alternative splicing of the IgIII loop of fibroblast growth factor receptors (FGFRs) 1–3 produces b- and c-variants of the receptors with distinctly different biological impact based on their distinct ligand-binding spectrum. Tissue-specific expression of these splice variants regulates interactions in embryonic development, tissue maintenance and repair, and cancer. Alterations in FGFR2 splicing are involved in epithelial mesenchymal transition that produces invasive, metastatic features during tumor progression. Recent research has elucidated regulatory factors that determine the splice choice both on the level of exogenous signaling events and on the RNA-protein interaction level. Moreover, methodology has been developed that will enable the in depth analysis of splicing events during tumorigenesis and provide further insight on the role of FGFR 1–3 IIIb and IIIc in the pathophysiology of various malignancies. This paper aims to summarize expression patterns in various tumor types and outlines possibilities for further analysis and application.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom